Omnicell Inc
NASDAQ:OMCL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Omnicell Inc
Total Receivables
Omnicell Inc
Total Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Omnicell Inc
NASDAQ:OMCL
|
Total Receivables
$216.9m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
3%
|
CAGR 10-Years
7%
|
|
|
Veeva Systems Inc
NYSE:VEEV
|
Total Receivables
$1.3B
|
CAGR 3-Years
19%
|
CAGR 5-Years
16%
|
CAGR 10-Years
25%
|
|
|
Teladoc Health Inc
NYSE:TDOC
|
Total Receivables
$201.7m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
4%
|
CAGR 10-Years
33%
|
|
|
Inspire Medical Systems Inc
NYSE:INSP
|
Total Receivables
$119.7m
|
CAGR 3-Years
25%
|
CAGR 5-Years
37%
|
CAGR 10-Years
N/A
|
|
|
Doximity Inc
NYSE:DOCS
|
Total Receivables
$135.9m
|
CAGR 3-Years
19%
|
CAGR 5-Years
39%
|
CAGR 10-Years
N/A
|
|
|
W
|
Waystar Holding Corp
NASDAQ:WAY
|
Total Receivables
$183.5m
|
CAGR 3-Years
18%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Omnicell Inc
Glance View
Omnicell Inc. stands at the intersection of healthcare and technology, sculpting the landscape of medication management systems with its innovative spirit. Founded in 1992, Omnicell has evolved from a small enterprise into a leading provider of automated solutions for medication and supply dispensing, inventory management, and analytics. The company’s core offering, its automated dispensing systems, reshapes how hospitals, pharmacies, and healthcare providers manage medications. By utilizing cutting-edge technology, Omnicell improves efficiency, reduces medication errors, and cuts down on healthcare costs. These systems are embedded in the workflow of healthcare facilities, ensuring that medication management becomes seamless, thus elevating patient safety and clinical outcomes. Revenue streams flow robustly from both product sales and associated services. Omnicell garners income by selling its advanced hardware systems, which include everything from pharmacy carousels to medication robotic systems, and supplements these sales with software solutions that offer predictive analytics and inventory optimization. Beyond the initial sale, a significant part of their business model includes recurring revenue through service contracts, software updates, and customer support. This dual approach not only ensures a steady cash flow but also strengthens customer relationships by consistently providing value over time. As the healthcare industry increasingly leans on technology for streamlined operations and cost management, Omnicell’s strategic positioning allows it to capitalize on the demand for sophisticated medication management solutions.
See Also
What is Omnicell Inc's Total Receivables?
Total Receivables
216.9m
USD
Based on the financial report for Dec 31, 2025, Omnicell Inc's Total Receivables amounts to 216.9m USD.
What is Omnicell Inc's Total Receivables growth rate?
Total Receivables CAGR 10Y
7%
Over the last year, the Total Receivables growth was -15%. The average annual Total Receivables growth rates for Omnicell Inc have been -10% over the past three years , 3% over the past five years , and 7% over the past ten years .